PE20001331A1 - Identificacion de genotipos senv - Google Patents
Identificacion de genotipos senvInfo
- Publication number
- PE20001331A1 PE20001331A1 PE1999001137A PE00113799A PE20001331A1 PE 20001331 A1 PE20001331 A1 PE 20001331A1 PE 1999001137 A PE1999001137 A PE 1999001137A PE 00113799 A PE00113799 A PE 00113799A PE 20001331 A1 PE20001331 A1 PE 20001331A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- dna
- virus
- orf
- nucleotides
- Prior art date
Links
- 108020004414 DNA Proteins 0.000 abstract 4
- 241000700605 Viruses Species 0.000 abstract 4
- 230000000295 complement effect Effects 0.000 abstract 3
- 239000003999 initiator Substances 0.000 abstract 2
- 239000002773 nucleotide Substances 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 102000015636 Oligopeptides Human genes 0.000 abstract 1
- 108010038807 Oligopeptides Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 238000005215 recombination Methods 0.000 abstract 1
- 230000006798 recombination Effects 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
SE REFIERE A UN ADN DE UN VIRUS QUE: a)CONTIENE COMO MINIMO UN ORF QUE CODIFICA UN POLIPEPTIDO DE SEQ ID NO 21, ENTRE OTROS; b)INCLUYE LA SECUENCIA DE ADN DE SEQ ID NO 2, ENTRE OTROS; c)COMPRENDE PORCIONES COMO MINIMO DE 80 NUCLEOTIDOS QUE HIBRIDAN EN CONDICIONES RESTRICTIVAS CON LA HEBRA COMPLEMENTARIA DEL ADN DE LA SEQ ID NO 26, ENTRE OTROS; d)ES DEGENERADA CON RESPECTO AL ADN ANTERIOR PERO NO HIBRIDA CON LA HEBRA COMPLEMENTARIA DEL GENOMA DEL VIRUS TT; e)ES COMO MINIMO 50% DEL ADN DE LA SEQ ID NO 26, ENTRE OTROS O CONTIENE UN ORF O UN FRAGMENTO DEL MISMO QUE ES COMO MINIMO 50% DE SEQ ID NO 28, ENTRE OTROS; f)PARTES DE ELLA PUEDEN AMPLIFICARSE POR PCR EN CONDICIONES ADECUADAS UTILIZANDO OLIGONUCLEOTIDOS INICIADORES DEFINIDOS EN SEQ ID NO 41, ENTRE OTROS; O LA CADENA COMPLEMENTARIA TAL COMO UN OLIGOPEPTIDO; g)SE DERIVA DE CUALQUIERA DE LAS MOLECULAS ANTERIORES POR INSERCION, SUSTITUCION, DELECION, INVERSION, DUPLICACION, RECOMBINACION, ADICION O UNA COMBINACION; CARACTERIZADO POR CODIFICAR 12 NUCLEOTIDOS, EL QUE CODIFICA UN EPITOPO QUE REACCIONA CON ANTICUERPOS PARA EL VIRUS SEN, INICIADOR O UNA SONDA. TAMBIEN SE REFIERE A UN METODO PARA PRODUCIR Y DETECTARUN POLIPEPTIDO, VIRUS, ANTICUERPO Y PUEDE SER UTIL PARA EL TRATAMIENTO DE HEPATOPATIAS (HEPATITIS), ENFERMEDAD INFLAMATORIA, (LUPUS) TRASTORNOS PROLIFERATIVOS (CANCER)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI982437 IT1303732B1 (it) | 1998-11-10 | 1998-11-10 | Molecole di acido nucleico che rappresentano un virus trasmissibileper via parenterale. |
| ITMI990923 IT1312552B1 (it) | 1999-04-30 | 1999-04-30 | Molecole di acido nucleico che rappresentano un virus trasmissibileper via parenterale |
| EP99830298 | 1999-05-14 | ||
| EP99113932 | 1999-07-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20001331A1 true PE20001331A1 (es) | 2000-12-19 |
Family
ID=27443821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1999001137A PE20001331A1 (es) | 1998-11-10 | 1999-11-10 | Identificacion de genotipos senv |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1137779A2 (es) |
| JP (1) | JP2002529092A (es) |
| AR (1) | AR021143A1 (es) |
| AU (1) | AU1381600A (es) |
| NO (1) | NO20012276L (es) |
| PE (1) | PE20001331A1 (es) |
| TN (1) | TNSN99210A1 (es) |
| WO (1) | WO2000028039A2 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1240189A2 (en) * | 1999-12-10 | 2002-09-18 | Roche Diagnostics GmbH | Hepatitis virus sentinel virus i (svi) |
| DE10007234A1 (de) * | 2000-02-17 | 2001-10-18 | Sension Biolog Detektions Und | Peptid und dafür kodierende Nukleinsäure zur Bestimmung, Diagnostik und Therapie von Erkrankungen des Nervensystems |
| DE10144346A1 (de) * | 2001-09-10 | 2003-04-03 | Deutsches Krebsforsch | TT-Virus-Sequenzen in menschlichen Tumorgeweben, Mittel zu deren Nachweis sowie Tumortherapie |
| US9676828B2 (en) | 2010-06-23 | 2017-06-13 | Deutsches Krebsforschungszentrum | Rearranged TT virus molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity |
| US20110318363A1 (en) | 2010-06-23 | 2011-12-29 | Deutsches Krebsforschungszentrum | Specific TT virus sequences and chimeric TT virus host cell DNA molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity |
| EP2399928B1 (en) * | 2010-06-23 | 2017-11-08 | Deutsches Krebsforschungszentrum | Specific TT virus sequences and chimeric TT virus host cell DNA molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity |
| PL2585477T3 (pl) * | 2010-06-23 | 2018-12-31 | Deutsches Krebsforschungszentrum | Rearanżowane cząsteczki wirusa tt do zastosowania w diagnozowaniu, profilaktyce i leczeniu raka oraz chorób autoimmunologicznych |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010022220A (ko) * | 1997-07-25 | 2001-03-15 | 다무라 료지 | 비-ｂ형 비-ｃ형 비-ｇ형 간염 바이러스 유전자,폴리뉴클레오티드, 폴리펩티드, 바이러스 입자, 바이러스입자의 분리 방법, 및 바이러스의 검출 방법 |
| AU4259299A (en) * | 1998-05-13 | 1999-11-29 | Innogenetics N.V. | New sequences of tt viruses for use in diagnosis, prevention and treatment of ttv infections |
-
1999
- 1999-11-08 TN TNTNSN99210A patent/TNSN99210A1/fr unknown
- 1999-11-09 WO PCT/EP1999/008566 patent/WO2000028039A2/en not_active Application Discontinuation
- 1999-11-09 JP JP2000581206A patent/JP2002529092A/ja active Pending
- 1999-11-09 AU AU13816/00A patent/AU1381600A/en not_active Abandoned
- 1999-11-09 EP EP99971855A patent/EP1137779A2/en not_active Withdrawn
- 1999-11-10 AR ARP990105694A patent/AR021143A1/es not_active Application Discontinuation
- 1999-11-10 PE PE1999001137A patent/PE20001331A1/es not_active Application Discontinuation
-
2001
- 2001-05-09 NO NO20012276A patent/NO20012276L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20012276D0 (no) | 2001-05-09 |
| WO2000028039A3 (en) | 2000-10-05 |
| EP1137779A2 (en) | 2001-10-04 |
| NO20012276L (no) | 2001-07-09 |
| TNSN99210A1 (fr) | 2005-11-10 |
| AR021143A1 (es) | 2002-06-12 |
| JP2002529092A (ja) | 2002-09-10 |
| WO2000028039A2 (en) | 2000-05-18 |
| AU1381600A (en) | 2000-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jones et al. | Genetic typing of bovine viral diarrhea virus isolates from Argentina | |
| Sanger | Determination of nucleotide sequences in DNA | |
| Ridpath et al. | Delayed onset postvaccinal mucosal disease as a result of genetic recombination between genotype 1 and genotype 2 BVDV | |
| ES2176342T3 (es) | Secuencias del genotipo 7 del virus de la hepatitis c y su utilizacioncomo agentes profilacticos, terapeuticos y de diagnostico. | |
| AR085952A2 (es) | Polinucleotidos cebadores | |
| Ridpath et al. | Comparison of the complete genomic sequence of the border disease virus, BD31, to other pestiviruses | |
| Cheah et al. | Site-directed mutagenesis suggests close functional relationship between a human rhinovirus 3C cysteine protease and cellular trypsin-like serine proteases. | |
| Rezelj et al. | Defective viral genomes as therapeutic interfering particles against flavivirus infection in mammalian and mosquito hosts | |
| ES2075901T3 (es) | Sistemas de expresion de virus recombinantes de arn con cadena negativa y vacunas. | |
| MX9700817A (es) | Secuencia viral de nucleotidos de "vr-2332" y metodos de uso. | |
| MXPA02005525A (es) | Clones infecciosos. | |
| CO5580165A1 (es) | Vacunas de rotavirus modificado | |
| Vilček et al. | Cellular insertions in the NS2-3 genome region of cytopathic bovine viral diarrhoea virus (BVDV) isolates | |
| PE20001331A1 (es) | Identificacion de genotipos senv | |
| WO2002072802A3 (en) | Live attenuated strains of prrs virus | |
| Kleine Büning et al. | Nonreplicative RNA recombination of an animal plus-strand RNA virus in the absence of efficient translation of viral proteins | |
| Carpenter et al. | Formation of multimers of linear satellite RNAs | |
| Haas et al. | Analysis of the H gene, the central untranslated region and the proximal coding part of the F gene of wild-type and vaccine canine distemper viruses | |
| ES2286212T3 (es) | Secuencias suprimidas especificamente del genoma de mycobacterium tuberculosis, y su uso en el diagnostico y como vacunas. | |
| CA2430582A1 (en) | A method for in vitro molecular evolution of protein function | |
| Desport et al. | Genome instability in BVDV: an examination of the sequence and structural influences on RNA recombination | |
| CU23245A1 (es) | CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS | |
| BR0112486A (pt) | Poliproteìna, molécula de ácido nucleico, plasmìdeo, vacina recombinante ou vacina atenuada, composição farmacêutica, e, método para imunizar um indivìduo contra hiv | |
| CU22666A1 (es) | Procedimiento para la expresión de genes de los virus del dengue en la levadura pichia pastoris, adns recombinantes y microorganismos transformados | |
| GB2362212A (en) | Method for the identification and speciation of bacteria of the burkholderia cepacia complex |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |